As the world population nears the 8 billion mark, Novartis is celebrating the delivery of 1 billion antimalarial treatments since 1999. That is the equivalent of 1 in 8 people living on our planet!
Novartis is committed to transforming the lives of people living with blood cancers and serious blood disorders.
With a breakthrough approval 20 years ago, Novartis opened the door to reimagine CML and other cancers. The pursuit of bold science didn’t stop there.
Understanding asthma: What are your misconceptions? This World Asthma Day find out more about asthma and challenge your misconceptions.
Novartis announced the company’s financial results for the first quarter of 2021.
This year, World Malaria Day is running with the backdrop of countries around the world continuing to fight the COVID-19 pandemic.
Together with partners, Novartis is committed to reimagining the fight against Chagas disease and advocating for an integrated, end-to-end care approach.
Together with local partners, Novartis aims to initiate a watershed development project near its own and supply chain operations in the Telangana region.
Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society ESG report.
This site is intended for a global audience.